PF-06291874 exhibits a diverse range of bioactivities, including significant permeability properties, receptor binding affinities, and varied inhibitory and modulatory effects across multiple cell types and receptors. It demonstrates apparent permeability across MDCK2 cells (Papp 3.6 ucm/s) and human Caco-2 cells (Papp 30.0 ucm/s at pH 6.5 and 8.5 ucm/s at pH 7.4), as well as across dog RRCK cells (8.5 x 10^-6 cm/s). It acts as an antagonist at various glucagon receptors in species including human, monkey, dog, mouse, and rats, with Kb values from 82.0 nM to 3900.0 nM, and displaces [125I]-glucagon-cex from the human glucagon receptor with a Ki value of 14.0 nM. The compound shows specific binding affinity to GLP-1 receptors (Ki 3160.0 nM) and inhibits the rat GABA-gated chloride channel (Ki 8200.0 nM).
In terms of pharmacokinetics, PF-06291874 has 100% oral bioavailability in both Beagle dogs (5 mg/kg, half-life 2.5 hours, Vdss 0.31 L/kg) and Wistar-Han rats (50 mg/kg, half-life 1.8 hours, Vdss 0.4 L/kg). It also shows plasma clearance rates in Beagle dogs (1.5 mL/min/kg) and Wistar-Han rats (2.8 mL/min/kg). With a log D value of 2.5 at pH 7.4, the compound also demonstrates significant cytotoxicity against human THLE cells (IC50 112000.0 nM).
Additionally, PF-06291874 shows cell type-dependent effects on cell viability, with varying growth rates in HEK293T, U2OS, and human fibroblast cells. Thermal Shift Assay results indicate that it has both stabilizing and destabilizing effects on different protein domains.
Notably, it has a broad spectrum of GPCR activities, showing positive modulation on GPR119 (2.783% maximal response), and inhibitory effects on CX3CR1, ADRB2, APLNR, FPR2, ADRA2A, C5AR1, and S1PR1 among others, with varying levels of inhibition. Furthermore, it exhibits both maximal response and inhibition at different concentrations on targets like FFAR4, AGTR1, GPR35, and GLP1R, thus highlighting its extensive and diverse bioactivity profile..
Note: Summary generated by AI. Data source: ChEMBL 